225Ac-ETN029

Other

Also known as ESP359

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT07006727 · Novartis Pharmaceuticals
2025-10-16 – 2031-08-29 · Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
What this study did

Competitive landscape

2 other tracked programmes target this mechanism.

This drug's own stage for Advanced Solid Tumors: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
225Ac-ETN029: this drugStage not on recordRadioligand Therapy (actinium-225)DLL3not yet gradedNo reviewed efficacy summary in this indication
AZD4956
Phase 1/2(overall)
Small moleculePOLQ (DNA polymerase theta)not yet gradedNo reviewed efficacy summary in this indication
BMS-986517Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BMS-986548
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
DJI136
Phase 1/2(overall)
Cell therapyDLL3
not yet graded(overall)
No reviewed efficacy summary in this indication
HRS-6768Phase 1/2UndisclosedFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
HRS-8364Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Palacaparib
Phase 1/2(overall)
Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
REGN10597Phase 1/2Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
SHR-1681Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4298
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4375Phase 1/2Antibody–drug conjugateTissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF)not yet gradedNo reviewed efficacy summary in this indication
SHR-4610Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-7787Phase 1/2Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
SHR-9803Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-188
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-505
Phase 1/2(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ABBV-253Phase 1Biologic (subtype unspecified)c-METnot yet gradedNo reviewed efficacy summary in this indication
BMS-986500Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5533524Phase 1Antibody–drug conjugateMUC16not yet gradedNo reviewed efficacy summary in this indication
HRS-6093Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JNJ-87890387Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JNJ-89862175Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
MP0310Phase 1Protein / enzyme therapeuticFAP x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
SHR-3821Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4685
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-4849Phase 1Antibody–drug conjugateDLL3not yet gradedNo reviewed efficacy summary in this indication
SHR-7782
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TAK-168
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
YS-ON-001Phase 1Biologic (subtype unspecified)TLR3 (poly I:C adjuvant)not yet gradedNo reviewed efficacy summary in this indication
AAA614
—(overall)
Radioligand TherapyFibroblast Activation Protein (FAP)not yet gradedNo reviewed efficacy summary in this indication
AZD5863
—(overall)
Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD9793
—(overall)
Multispecific antibodyGlypican-3 (GPC3) x CD3not yet gradedNo reviewed efficacy summary in this indication
BMS-986506
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GCJ904
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5460025
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
PF-08032560
—(overall)
Small moleculeKAT6A/KAT6B and KAT7not yet gradedNo reviewed efficacy summary in this indication
PF-08046044
—(overall)
Antibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
RG6505
—(overall)
UndisclosedRAS (pan-RAS, RAS-mutant tumors)not yet gradedNo reviewed efficacy summary in this indication
RG6620
—(overall)
UndisclosedKRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
RG6648
—(overall)
Antibody–drug conjugatec-METnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow 225Ac-ETN029 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
August 2031 (1)
Phase 1Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer …Recruiting
Est. primary completion 2031-08-29 · NCT07006727 · CT.gov ↗
What to watch

See the full readout calendar ↗